首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >Technique and early clinical outcomes for spinal and paraspinal tumours treated with stereotactic body radiotherapy
【24h】

Technique and early clinical outcomes for spinal and paraspinal tumours treated with stereotactic body radiotherapy

机译:用立体定向体放射治疗脊柱和肩胛骨肿瘤的技术及早期临床结果

获取原文
获取原文并翻译 | 示例
           

摘要

We report technique and early clinical results of stereotactic body radiotherapy (SBRT) from Princess Alexandra Hospital. SBRT involves the precise delivery of highly conformal and image-guided external beam radiotherapy with high doses per fraction. It is increasingly being applied in management of spinal tumours. Thirty-six courses of spine SBRT in 34 patients were delivered between May 2010 and December 2013. Mean patient age was 58 years. Treatment was predominantly for metastatic disease, applied in de novo (n = 22), retreatment (n = 14) and postoperative (n = 8) settings. Prescribed doses included 18-30 Gy in 1-5 fractions. SBRT technique evolved during the study period, resulting in a relative dose escalation. No severe acute toxicities were observed. At median follow-up of 7.4 months (range: 1.7-22.2), no late radiation myelopathy was observed. Risk of new/worsening vertebral compression fractures was 22% (n = 8) and was significantly associated with increasing Spinal Instability Neoplastic Scores (p = 0.0002). In-field control was 86% with relapse occurring at a median interval of 2.8 months (range: 1.9-4.7). Thirteen patients (36%) died and median overall survival has not been reached. SBRT is an evolving technology with promising early efficacy and safety results. The outcomes of this series are comparable with international literature, and await longer follow-up.
机译:我们从亚历山德拉医院报告了立体定向体放射治疗(SBRT)的技术和早期临床结果。 SBRT涉及每馏分高剂量和高剂量的高剂量和图像引导外梁放射疗法的精确递送。越来越多地应用于脊柱肿瘤的管理。 2010年5月至2013年12月之间的34名患者的34名脊柱SBRT课程是患者年龄在58年之间进行的。治疗主要用于转移性疾病,施用在Novo(n = 22),后退(n = 14)和术后(n = 8)设置。规定剂量包括1-5个级分中的18-30gy。 SBR技术在研究期间进化,导致相对剂量升级。没有观察到严重的急性毒性。在中位随访7.4个月(范围:1.7-22.2),没有观察到晚期辐射病变。新/恶化的椎体压缩骨折的风险为22%(n = 8),与增加脊柱不稳定肿瘤分数显着相关(p = 0.0002)。现场控制为86%,复发发生在2.8个月(范围:1.9-4.7)。 13名患者(36%)死亡,尚未达到中位数生存。 SBRT是一种不断发展的技术,具有有前景的早期疗效和安全结果。该系列的结果与国际文献相当,等待更长的随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号